Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

| Atara Biotherapeutics, Inc. Form 4 Form 4 February 08, 2017 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL Check this box if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES MB 3235-0287 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. See Instruction 17(a) of the Public Utility Holding Company Act of 1935 or Section 17(a) of the Public Utility Holding Company Act of 1940 Expires: 0.5 | | | | | | | | |
|--|--|---|--|--|------------------|--|--|--|
| (Print or Type Responses) | | | | | | | | |
| 1. Name and Address of Reporting Person Haqq Christopher | Symbol | Ticker or Trading | 5. Relationship of Reporting Person(s) to Issuer | | | | | |
| (Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900 | 3. Date of Earliest Tr (Month/Day/Year) 02/06/2017 | ansaction | (Check all applicable) <u>Director</u> 10% Owner <u>X</u> Officer (give title Other (specify below) EVP, R&D & Chief Scientific Of | | | | | |
| (Street) SOUTH SAN | te Original | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| FRANCISCO, CA 94080 | | | | | | | | |
| (City)(State)(Zip)Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | |
| | cution Date, if Transaction | | Securities Beneficially Owned | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | | | |
| Common 02/06/2017 Stock | А | 49,500 A \$0 | 413,605 | D | | | | |
| Common Stock | | | 17,312 | I | See footnote (2) | | | |
| Common Stock | | | 2,688 | I | See footnote (3) | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transactio Code (Instr. 8) | 5. 6. Date Exercisable and ionNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, | | Date | Secur | ınt of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr |
|---|---|---|--|--|---------------------|--------------------|-------|--|---|--|
| Beno | rtina O | wners | Code V | 4, and 5) (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

neporting **Owners**

| Reporting Owner Name / Address | Relationships | | | | | |
|---|-------------------|------------------|--------------------------------|-------|--|--|
| | irector | 10% Owner | Officer | Other | | |
| Haqq Christopher 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080 | | | EVP, R&D & Chief Scientific Of | | | |
| Signatures | | | | | | |
| /s/ Tina Gullotta, Attorney-in-Fact for Chris Haqq | stopher | (|)2/08/2017 | | | |
| **Signature of Reporting Person | | | Date | | | |
| Explanation of Response | es: | | | | | |
| * If the form is filed by more than one reporting pe | erson, <i>see</i> | e Instruction 4(| b)(v). | | | |

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant (1) date, subject to the reporting person's continuous service.
- (2) The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- (3) The shares are held by The Havenside Trust, of which the Reporting Person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.